Cost-effectiveness analysis of adult pneumococcal conjugate vaccines for pneumococcal disease in Japan
Open Access
- 9 May 2024
- journal article
- research article
- Published by Taylor & Francis in Expert Review of Vaccines
- Vol. 23 (1) , 546-560
Abstract
The 23-valent pneumococcal polysaccharide vaccine (PPSV23) is used in the Japanese National Immunization Program for older adults and adults with increased risk for pneumococcal disease, however, disease incidence and associated burden remain high. We evaluated the cost-effectiveness of pneumococcal conjugate vaccines (PCVs) for adults aged 65 years and high-risk adults aged 60-64 years in Japan. Using a Markov model, we evaluated lifetime costs using societal and healthcare payer perspectives and estimated quality-adjusted life-years (QALYs), and number of prevented cases and deaths caused by invasive pneumococcal disease (IPD) and non-IPD. The base case analysis used a societal perspective. In comparison with PPSV23, the 20-valent PCV (PCV20) prevented 127 IPD cases 10,813 non-IPD cases (inpatients: 2,461, outpatients: 8,352) and 226 deaths, and gained more QALYs (+0.0015 per person) with less cost (-JPY22,513 per person). All sensitivity and scenario analyses including a payer perspective analysis indicated that the incremental cost-effectiveness ratios (ICERs) were below the cost-effectiveness threshold value in Japan (JPY5 million/QALY). PCV20 is both cost saving and more effective than PPSV23 for adults aged 65 years and high-risk adults aged 60-64 years in Japan.Keywords
Funding Information
- Pfizer Japan Inc
This publication has 57 references indexed in Scilit:
- Community-Acquired Pneumonia Incidence in Adults Aged 18 Years and Older in Goto City, JapanCHEST Pulmonary, 2023
- Serotype distribution and antimicrobial susceptibility of Streptococcus pneumoniae associated with invasive pneumococcal disease among adults in JapanInternational Journal of Infectious Diseases, 2021
- Effectiveness of 23-Valent Polysaccharide Pneumococcal Vaccine and Changes in Invasive Pneumococcal Disease Incidence from 2000 to 2017 in Those Aged 65 and Over in England and WaleseClinicalMedicine, 2018
- Incremental Cost-Effectiveness of 13-valent Pneumococcal Conjugate Vaccine for Adults Age 50 Years and Older in the United StatesJournal of General Internal Medicine, 2016
- Japanese population norms for preference-based measures: EQ-5D-3L, EQ-5D-5L, and SF-6DQuality of Life Research, 2015
- Association Between Hospitalization for Pneumonia and Subsequent Risk of Cardiovascular DiseaseJAMA, 2015
- Modeling of Cost Effectiveness of Pneumococcal Conjugate Vaccination Strategies in U.S. Older AdultsAmerican Journal of Preventive Medicine, 2013
- Vaccines for preventing pneumococcal infection in adultsCochrane Database of Systematic Reviews, 2013
- Effect of Pneumococcal Vaccination in Hospitalized Adults With Community-Acquired PneumoniaArchives of internal medicine (1960), 2007
- Cost-effectiveness of pneumococcal vaccination for prevention of invasive pneumococcal disease in the elderly: an update for 10 Western European countriesEuropean Journal of Clinical Microbiology & Infectious Diseases, 2007